Mainz Biomed Enters Commercial Partnership For ColoAlert With Fugene Genetics In Israel
Portfolio Pulse from Benzinga Newsdesk
Mainz Biomed has entered into a commercial partnership with Fugene Genetics for ColoAlert in Israel. This partnership is expected to expand the reach of ColoAlert, a non-invasive colorectal cancer screening test, in the Israeli market.
July 18, 2023 | 7:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mainz Biomed's partnership with Fugene Genetics for ColoAlert in Israel could potentially increase the company's market reach and revenues.
The partnership with Fugene Genetics allows Mainz Biomed to expand the reach of its product, ColoAlert, in the Israeli market. This could potentially lead to increased sales and revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100